Cardiac troponin assays: A review of quantitative point-of-care devices and their efficacy in the diagnosis of myocardial infarction

Beret E. Amundson; Fred S. Apple

doi:10.1515/cclm-2014-0837

Cardiac troponin assays: A review of quantitative point-of-care devices and their efficacy in the diagnosis of myocardial infarction

Beret E. Amundson, Fred S. Apple

Research output: Contribution to journal › Review article › peer-review

57 Scopus citations

Abstract

Cardiac troponin (cTn) I and T are released from myocardial cells following necrosis, i.e., cell death. An accurate measure of cTn concentrations in a patient's blood following ischemia/chest pain can enable providers to determine whether or not a myocardial infarction (MI) has occurred. Point-of-care (POC) devices that measure blood cTn concentrations in under 30 min may help to significantly reduce hospital costs by managing and triaging patients out of the emergency department as quickly as possible. The use of POC devices that measure cTnI and cTnT with a coefficient of variation (CV) ≤20% at the 99th percentile upper reference limit (URL) limits both false positive and negative results and provides clinically acceptable findings to assist in appropriate diagnoses. This article reviews nine POC devices that measure cTn in terms of their clinical sensitivity and specificity, analytical imprecision, sample type and preparation, and each assay's principle of analysis.

Original language	English (US)
Pages (from-to)	665-676
Number of pages	12
Journal	Clinical Chemistry and Laboratory Medicine
Volume	53
Issue number	5
DOIs	https://doi.org/10.1515/cclm-2014-0837
State	Published - Apr 1 2015
Externally published	Yes

Bibliographical note

Funding Information:
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission. Financial support: Professor Apple s research laboratory at the Minneapolis Medical Research Foundation of Hennepion County Medical Center has received research funding from the large majority of biomarker companies that manufacture and market cTnI and cTnT assays. Employment or leadership: None declared. Honorarium: None declared. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Publisher Copyright:
© 2015 by De Gruyter.

Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.

Keywords

cardiac troponin
immunoassay
point-of-care

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1515/cclm-2014-0837

Find It

Find It at U of M Libraries

Cite this

@article{0b017446fd7c412ca3bfeb4a7865c143,

title = "Cardiac troponin assays: A review of quantitative point-of-care devices and their efficacy in the diagnosis of myocardial infarction",

abstract = "Cardiac troponin (cTn) I and T are released from myocardial cells following necrosis, i.e., cell death. An accurate measure of cTn concentrations in a patient's blood following ischemia/chest pain can enable providers to determine whether or not a myocardial infarction (MI) has occurred. Point-of-care (POC) devices that measure blood cTn concentrations in under 30 min may help to significantly reduce hospital costs by managing and triaging patients out of the emergency department as quickly as possible. The use of POC devices that measure cTnI and cTnT with a coefficient of variation (CV) ≤20% at the 99th percentile upper reference limit (URL) limits both false positive and negative results and provides clinically acceptable findings to assist in appropriate diagnoses. This article reviews nine POC devices that measure cTn in terms of their clinical sensitivity and specificity, analytical imprecision, sample type and preparation, and each assay's principle of analysis.",

keywords = "cardiac troponin, immunoassay, point-of-care",

author = "Amundson, {Beret E.} and Apple, {Fred S.}",

note = "Funding Information: Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission. Financial support: Professor Apple s research laboratory at the Minneapolis Medical Research Foundation of Hennepion County Medical Center has received research funding from the large majority of biomarker companies that manufacture and market cTnI and cTnT assays. Employment or leadership: None declared. Honorarium: None declared. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication. Publisher Copyright: {\textcopyright} 2015 by De Gruyter. Copyright: Copyright 2016 Elsevier B.V., All rights reserved.",

year = "2015",

month = apr,

day = "1",

doi = "10.1515/cclm-2014-0837",

language = "English (US)",

volume = "53",

pages = "665--676",

journal = "Clinical Chemistry and Laboratory Medicine",

issn = "1434-6621",

publisher = "Walter de Gruyter GmbH",

number = "5",

}

TY - JOUR

T1 - Cardiac troponin assays

T2 - A review of quantitative point-of-care devices and their efficacy in the diagnosis of myocardial infarction

AU - Amundson, Beret E.

AU - Apple, Fred S.

N1 - Funding Information: Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission. Financial support: Professor Apple s research laboratory at the Minneapolis Medical Research Foundation of Hennepion County Medical Center has received research funding from the large majority of biomarker companies that manufacture and market cTnI and cTnT assays. Employment or leadership: None declared. Honorarium: None declared. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication. Publisher Copyright: © 2015 by De Gruyter. Copyright: Copyright 2016 Elsevier B.V., All rights reserved.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Cardiac troponin (cTn) I and T are released from myocardial cells following necrosis, i.e., cell death. An accurate measure of cTn concentrations in a patient's blood following ischemia/chest pain can enable providers to determine whether or not a myocardial infarction (MI) has occurred. Point-of-care (POC) devices that measure blood cTn concentrations in under 30 min may help to significantly reduce hospital costs by managing and triaging patients out of the emergency department as quickly as possible. The use of POC devices that measure cTnI and cTnT with a coefficient of variation (CV) ≤20% at the 99th percentile upper reference limit (URL) limits both false positive and negative results and provides clinically acceptable findings to assist in appropriate diagnoses. This article reviews nine POC devices that measure cTn in terms of their clinical sensitivity and specificity, analytical imprecision, sample type and preparation, and each assay's principle of analysis.

AB - Cardiac troponin (cTn) I and T are released from myocardial cells following necrosis, i.e., cell death. An accurate measure of cTn concentrations in a patient's blood following ischemia/chest pain can enable providers to determine whether or not a myocardial infarction (MI) has occurred. Point-of-care (POC) devices that measure blood cTn concentrations in under 30 min may help to significantly reduce hospital costs by managing and triaging patients out of the emergency department as quickly as possible. The use of POC devices that measure cTnI and cTnT with a coefficient of variation (CV) ≤20% at the 99th percentile upper reference limit (URL) limits both false positive and negative results and provides clinically acceptable findings to assist in appropriate diagnoses. This article reviews nine POC devices that measure cTn in terms of their clinical sensitivity and specificity, analytical imprecision, sample type and preparation, and each assay's principle of analysis.

KW - cardiac troponin

KW - immunoassay

KW - point-of-care

UR - http://www.scopus.com/inward/record.url?scp=84928008673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928008673&partnerID=8YFLogxK

U2 - 10.1515/cclm-2014-0837

DO - 10.1515/cclm-2014-0837

M3 - Review article

C2 - 25324453

AN - SCOPUS:84928008673

SN - 1434-6621

VL - 53

SP - 665

EP - 676

JO - Clinical Chemistry and Laboratory Medicine

JF - Clinical Chemistry and Laboratory Medicine

IS - 5

ER -

Cardiac troponin assays: A review of quantitative point-of-care devices and their efficacy in the diagnosis of myocardial infarction

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this